GTC
ABOS icon

Ghost Tree Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Ghost Tree Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,000
Closed -$623K – 53
2023
Q3 		$623K Buy
+150,000
New +$927K 0.2% 65

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ghost Tree Capital's ABOS Position: Q4 2023 in Review

Ghost Tree Capital sold out of Acumen Pharmaceuticals (ABOS) in Q4 2023, closing a stake of 150,000 shares — an estimated $623K sold.

Ghost Tree Capital first reported a position in ABOS in Q3 2023 and held it in 1 quarter. The position peaked at $623K in Q3 2023. 67 funds tracked by Wall St. Rank hold ABOS as of Q4 2023.

  • Ghost Tree Capital reported no remaining Acumen Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 150,000 Acumen Pharmaceuticals shares in Q4 2023, an estimated $623K.
  • Ghost Tree Capital first reported a position in Acumen Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Ghost Tree Capital's Acumen Pharmaceuticals position peaked at $623K in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.